Cantor Fitzgerald analyst Kristen Kluska downgraded ADMA Biologics (NASDAQ: ADMA) from Overweight to Neutral.The analyst comments: "Following ADMA shares trading ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE